| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in investing activities | -23,742 | 24,283 |
| Proceeds from employee stock purchase plan and exercise of stock options | 1,617 | 1,460 |
| Proceeds related to common stock financings, net | 109,724 | 254 |
| Proceeds (principal payments), net for tenant improvement loan | -258 | -171 |
| Net cash provided by financing activities | 111,083 | 1,543 |
| Net decrease in cash, cash equivalents, and restricted cash | -23,846 | -55,932 |
| Cash and cash equivalents at beginning of period | 131,398 | - |
| Cash and cash equivalents at end of period | 107,552 | - |
Sana Biotechnology, Inc. (SANA)
Sana Biotechnology, Inc. (SANA)